The aim – to examine the effectiveness of the trimetazidine and its metabolic influences in patients with ischemic heart disease.
Material and methods. The pilot study was conducted in 10 patients (6 women and 4 men) aged 49–80 years with stable angina pectoris I–III functional class NYHA. All patients were examined at baseline and after 1 month of therapy with trimetazidine 35 mg twice daily.
Results. After 1 month of therapy with trimetazidine we noted decreased number of angina attacks by 2.39 times and reduce of their duration by 2.32 times. We also observed decrease in index-induced apoptosis, normalization of lipid peroxidation (malondialdehyde reducing and increasing antioxidant status), increase of HDL cholesterol, lower levels of uric acid and C-reactive protein.
Conclusions. These data show clinical efficacy of trimetazidine and its positive effects upon metabolic processes.